Regeneron agreed to a multi‑million dollar collaboration with Tessera to advance a near‑clinic gene‑writing program for alpha‑1 antitrypsin deficiency (AATD). Public filings and press reports show Regeneron committed roughly $150 million in upfront capital to accelerate Tessera’s TSRA‑196 toward clinical development and commercialization. The deal pairs Regeneron’s clinical and regulatory capacity with Tessera’s gene‑writing platform, an approach that aims to install or rewrite genomic sequences in vivo rather than rely on traditional nuclease editing. The partnership signals deepening industry interest in in vivo gene‑writing as companies move from discovery to first‑in‑human programs. Gene writing is a nascent modality that seeks to program cellular DNA directly at scale; it differs from CRISPR by emphasizing templated writing of new sequences. For investors and developers, the pact transfers near‑term clinical execution risk to Regeneron while validating Tessera’s platform technology. Sources: company statements and industry reporting on the Regeneron–Tessera agreement.